Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia

Yei Mei Peng, David S Alberts, Vivian Graham, Earl A. Surwit, Sheldon Weiner, Frank L. Meyskens

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The present study was undertaken to evaluate the systemic absorption and cervical tissue uptake of all-transretinoic acid (TRA), delivered via a collagen spongecervical cap delivery device in patients with intraepithelial cervical dysplasia. Ten patients with histologically proven mild or moderate cervical dysplasia were included in this pharmacologic study. The two TRA concentrations (0.05% and 0.372%) selected for study represent the starting and maximally tolerated doses used in phase I clinical trial. All-trans-retinoic-11-3H acid (3H-TRA, 500 μCi) was used to facilitate cervical tissue uptake studies. Cervical biopsies and post-treatment blood samples were obtained from each patient after TRA exposure. The uptake of TRA into cervical tissues four hours after drug administration was significantly increased at the maximally tolerated TRA dose. There was a rapid decrease in cervical tissue concentration of TRA at the 0.372% dose between 4 and 24 h after drug exposure, suggesting a relatively short elimination half-life of TRA in cervical tissues. HPLC analysis of post-treatment blood samples indicate that there was no systemic absorption of TRA after local cervical administration.

Original languageEnglish (US)
Pages (from-to)245-249
Number of pages5
JournalInvestigational New Drugs
Volume4
Issue number3
DOIs
StatePublished - Sep 1986

Fingerprint

Female Contraceptive Devices
Uterine Cervical Dysplasia
Porifera
Tretinoin
Collagen
Equipment and Supplies
Acids
Clinical Trials, Phase I
Maximum Tolerated Dose
Pharmaceutical Preparations
Half-Life
High Pressure Liquid Chromatography

Keywords

  • all-trans-retinoic acid
  • cervical dysplasia
  • collagen sponge-cervical cap
  • tissue uptake of anticancer drug

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia. / Peng, Yei Mei; Alberts, David S; Graham, Vivian; Surwit, Earl A.; Weiner, Sheldon; Meyskens, Frank L.

In: Investigational New Drugs, Vol. 4, No. 3, 09.1986, p. 245-249.

Research output: Contribution to journalArticle

Peng, Yei Mei ; Alberts, David S ; Graham, Vivian ; Surwit, Earl A. ; Weiner, Sheldon ; Meyskens, Frank L. / Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia. In: Investigational New Drugs. 1986 ; Vol. 4, No. 3. pp. 245-249.
@article{a8a3a347d4b645b7b974293420767362,
title = "Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia",
abstract = "The present study was undertaken to evaluate the systemic absorption and cervical tissue uptake of all-transretinoic acid (TRA), delivered via a collagen spongecervical cap delivery device in patients with intraepithelial cervical dysplasia. Ten patients with histologically proven mild or moderate cervical dysplasia were included in this pharmacologic study. The two TRA concentrations (0.05{\%} and 0.372{\%}) selected for study represent the starting and maximally tolerated doses used in phase I clinical trial. All-trans-retinoic-11-3H acid (3H-TRA, 500 μCi) was used to facilitate cervical tissue uptake studies. Cervical biopsies and post-treatment blood samples were obtained from each patient after TRA exposure. The uptake of TRA into cervical tissues four hours after drug administration was significantly increased at the maximally tolerated TRA dose. There was a rapid decrease in cervical tissue concentration of TRA at the 0.372{\%} dose between 4 and 24 h after drug exposure, suggesting a relatively short elimination half-life of TRA in cervical tissues. HPLC analysis of post-treatment blood samples indicate that there was no systemic absorption of TRA after local cervical administration.",
keywords = "all-trans-retinoic acid, cervical dysplasia, collagen sponge-cervical cap, tissue uptake of anticancer drug",
author = "Peng, {Yei Mei} and Alberts, {David S} and Vivian Graham and Surwit, {Earl A.} and Sheldon Weiner and Meyskens, {Frank L.}",
year = "1986",
month = "9",
doi = "10.1007/BF00179591",
language = "English (US)",
volume = "4",
pages = "245--249",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia

AU - Peng, Yei Mei

AU - Alberts, David S

AU - Graham, Vivian

AU - Surwit, Earl A.

AU - Weiner, Sheldon

AU - Meyskens, Frank L.

PY - 1986/9

Y1 - 1986/9

N2 - The present study was undertaken to evaluate the systemic absorption and cervical tissue uptake of all-transretinoic acid (TRA), delivered via a collagen spongecervical cap delivery device in patients with intraepithelial cervical dysplasia. Ten patients with histologically proven mild or moderate cervical dysplasia were included in this pharmacologic study. The two TRA concentrations (0.05% and 0.372%) selected for study represent the starting and maximally tolerated doses used in phase I clinical trial. All-trans-retinoic-11-3H acid (3H-TRA, 500 μCi) was used to facilitate cervical tissue uptake studies. Cervical biopsies and post-treatment blood samples were obtained from each patient after TRA exposure. The uptake of TRA into cervical tissues four hours after drug administration was significantly increased at the maximally tolerated TRA dose. There was a rapid decrease in cervical tissue concentration of TRA at the 0.372% dose between 4 and 24 h after drug exposure, suggesting a relatively short elimination half-life of TRA in cervical tissues. HPLC analysis of post-treatment blood samples indicate that there was no systemic absorption of TRA after local cervical administration.

AB - The present study was undertaken to evaluate the systemic absorption and cervical tissue uptake of all-transretinoic acid (TRA), delivered via a collagen spongecervical cap delivery device in patients with intraepithelial cervical dysplasia. Ten patients with histologically proven mild or moderate cervical dysplasia were included in this pharmacologic study. The two TRA concentrations (0.05% and 0.372%) selected for study represent the starting and maximally tolerated doses used in phase I clinical trial. All-trans-retinoic-11-3H acid (3H-TRA, 500 μCi) was used to facilitate cervical tissue uptake studies. Cervical biopsies and post-treatment blood samples were obtained from each patient after TRA exposure. The uptake of TRA into cervical tissues four hours after drug administration was significantly increased at the maximally tolerated TRA dose. There was a rapid decrease in cervical tissue concentration of TRA at the 0.372% dose between 4 and 24 h after drug exposure, suggesting a relatively short elimination half-life of TRA in cervical tissues. HPLC analysis of post-treatment blood samples indicate that there was no systemic absorption of TRA after local cervical administration.

KW - all-trans-retinoic acid

KW - cervical dysplasia

KW - collagen sponge-cervical cap

KW - tissue uptake of anticancer drug

UR - http://www.scopus.com/inward/record.url?scp=0023026031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023026031&partnerID=8YFLogxK

U2 - 10.1007/BF00179591

DO - 10.1007/BF00179591

M3 - Article

VL - 4

SP - 245

EP - 249

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -